undamentalytics Newsletter
Sign in

Ionis Pharmaceuticals Inc income statement

In fiscal 2025, Ionis Pharmaceuticals Inc reported revenue of $944m, up 33.8% on the year before, operating income of −$382m (a -40.4% margin) and net income of −$381m, or −$2.38 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue122108991021472142843475086001,123729810587788705944874
Cost of revenue———————00241211149111616
Gross profit———————3475085981,118717800573779694928858
Research and development135145153155174239320340373412462531638—900902916—
Selling, general and administrative——————3749108245287354186150233267394528
General and administrative151213131520————————————
Operating income−28−48−71−69−52−48−76−2031−61366−172−30−410−354−475−382−594
Interest expense1313172119223739454512109813171719
Income before tax−32−61−85−75−67−54−88−84−17−76339−135−29−258−334−460−380−562
Income tax300−9−6−1503−6−29152345−11232−623
Net income155−61−85−65−61−39−88−600274278−444−29−270−366−454−381−565
Diluted EPS$1.58−$0.62−$0.85−$0.65−$0.55−$0.33−$0.74−$0.50$0.15$2.07$1.90−$3.18−$0.20−$1.90−$2.56−$3.04−$2.38−$3.59
Diluted shares (average)98m99m100m101m111m118m120m121m126m134m153m140m141m142m143m150m160m157m
EBITDA−24−44−65−62−45−41−69−1338−51378−159−15−396−343−465−372−582

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ASND vs IONSBCRX vs IONSBBIO vs IONSIONS vs KNSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ionis Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ionis Pharmaceuticals Inc.